Bronchodilatory Effect of the PPAR‐γ Agonist Rosiglitazone in Smokers With Asthma

@article{Spears2009BronchodilatoryEO,
  title={Bronchodilatory Effect of the PPAR‐γ Agonist Rosiglitazone in Smokers With Asthma},
  author={M. Spears and I. Donnelly and L. Jolly and M. Brannigan and K. Ito and C. Mcsharry and J. Lafferty and R. Chaudhuri and G. Braganza and P. Bareille and L. Sweeney and I. Adcock and P. Barnes and S. Wood and N. Thomson},
  journal={Clinical Pharmacology & Therapeutics},
  year={2009},
  volume={86}
}
  • M. Spears, I. Donnelly, +12 authors N. Thomson
  • Published 2009
  • Medicine
  • Clinical Pharmacology & Therapeutics
  • Smokers with asthma show a reduced response to inhaled corticosteroids. We hypothesized that a peroxisome proliferator–activated receptor‐γ (PPAR‐γ) agonist would be superior for the clinical treatment of these asthma patients. Forty‐six smokers with asthma were randomized to inhaled beclometasone dipropionate (200 µg per day) or rosiglitazone (8 mg per day) for 4 weeks. Rosiglitazone produced improvements in lung function (forced expiratory volume in 1 s (FEV1) = 183 ml, P = 0.051; forced… CONTINUE READING

    Topics from this paper.

    PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy
    16
    Anti-inflammatory effects of thiazolidinediones in human airway smooth muscle cells.
    32

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 36 REFERENCES